Skip to main content
TipRanks
Go Ultimate75% OFF

Novonesis (NZM) Stock Price & Analysis

9 Followers

NZM Stock Chart & Stats

€60.50€0.00(0.00%)
At close: 5:30 PM GMT+1
€57.5€60€62.5Aug 26Oct 20
Day’s Range
EUR 60.50 - EUR 60.50
52-Week Range
EUR 44.80 - EUR 64.00
Previous Close
EUR 60.50
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 28.62B
Enterprise Value
EUR 32.86B
Total Cash (Recent Filing)
EUR 465.50M
Total Debt (Recent Filing)
EUR 3.18B
Price to Earnings (P/E)
40.9
Beta
0.33
Next Earnings
Feb 11, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
0.22%

Bulls Say, Bears Say

Bulls Say

Diversified Market Position

Balanced exposure across geographies and multiple end markets reduces dependence on any single customer cycle or sector. This diversification can make revenue more resilient through uneven demand, while Novonesis can redirect innovation and commercial focus toward stronger structural growth areas.

Strong Operating Margins And Cash Generation

High operating margins and positive, growing operating cash flow indicate that Novonesis converts differentiated biosolutions and pricing into meaningful internal funding. This supports continued research, customer support, capacity investment and balance-sheet management without relying solely on external capital.

Innovation And Technology Expansion

A sustained biosolutions launch cadence strengthens Novonesis’s ability to address healthier products, higher yields and more efficient production. Continued innovation can deepen customer integration, expand applications for its technology platforms and support durable growth beyond existing product demand.

Bears Say

Recent Net Loss And Earnings Quality

The divergence between healthy operating margins and a recent net loss signals pressure below the operating line and reduces confidence in earnings consistency. If this persists, it could weaken retained capital, constrain shareholder returns and make reported profitability less dependable over coming quarters.

Delayed North American Supplements Recovery

Weakness in North American dietary supplements is more than a single-quarter fluctuation because management has pushed the expected recovery into the second half of 2027. Continued declines and customer destocking can weigh on Human Health growth and leave the portfolio dependent on other divisions for momentum.

High Investment Burden And FCF Pressure

Elevated capital expenditure and weaker free cash flow reduce near-term financial flexibility even while the projects may support future capacity. The burden is expected to continue into 2027, potentially limiting cash available for acquisitions, buybacks, debt reduction or other shareholder-oriented uses.

Novonesis News

NZM FAQ

What was Novonesis’s price range in the past 12 months?
Novonesis lowest stock price was €44.80 and its highest was €64.00 in the past 12 months.
What is Novonesis’s market cap?
Novonesis’s market cap is €28.62B.
When is Novonesis’s upcoming earnings report date?
Novonesis’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 86 days.
How were Novonesis’s earnings last quarter?
Novonesis released its earnings results on Nov 05, 2026. The company reported €0.546 earnings per share for the quarter, missing the consensus estimate of €0.67 by -€0.123.
Is Novonesis overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Novonesis pay dividends?
Novonesis does not currently pay dividends.
What is Novonesis’s EPS estimate?
Novonesis’s EPS estimate is 0.59.
How many shares outstanding does Novonesis have?
Novonesis has 414,555,050 shares outstanding.
What happened to Novonesis’s price movement after its last earnings report?
Novonesis reported an EPS of €0.546 in its last earnings report, missing expectations of €0.67. Following the earnings report the stock price went up 4.132%.
Which hedge fund is a major shareholder of Novonesis?
Currently, no hedge funds are holding shares in DE:NZM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology